Acrivon Therapeutics Q3 2025 net loss $18.2M, cash $134.4M to fund into Q2 2027

Acrivon Therapeutics, Inc.

2025-Q3 EPS reported -$1.53 vs consensus -$0.60 ▼ miss (-154.2%)

Net loss of $18.2M for Q3 2025, improved from $22.4M in Q3 2024.
Cash, cash equivalents and investments of $134.4M as of Sep 30, 2025; funds operations into Q2 2027.
R&D expenses fell to $13.6M from $18.9M due to fewer milestones and trial prioritization.
Advancing ACR-368 Phase 2b trial for endometrial cancer; initial ACR-2316 Phase 1 data expected H2 2025.
Presented AP3 platform data at AACR-NCI-EORTC; new cell cycle program targets candidate nomination in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.